Next-Gen Cancer Treatment: Nanotechnology-Driven siRNA Delivery Solutions

Area of Science:

• Biomedical Engineering
• Oncology
• Nanotechnology

Background:

• RNA interference (RNAi) using small interfering RNA (siRNA) shows promise for cancer therapy.
• Efficient delivery of siRNA to target cancer cells remains a major obstacle.
• Bridging the gap between laboratory research and clinical application is crucial.

Purpose of the Study:

• To review recent advancements in nanotechnology-based siRNA delivery systems for cancer treatment.
• To highlight various nanocarrier platforms and their properties.
• To discuss challenges and future prospects for clinical translation.

Main Methods:

• Comprehensive literature search of PubMed, Scopus, and Web of Science.
• Screening of relevant articles on nanotechnology for siRNA delivery in cancer.
• Analysis of different nanocarrier types and their performance.

Main Results:

• Emergence of nanotechnology platforms offering enhanced siRNA selectivity, stability, and controlled release.
• Key nanocarrier types include lipid-based nanoparticles, inorganic nanoparticles, polymeric nanoparticles, and exosomes.
• Significant progress in preclinical studies demonstrating the potential of these systems.

Conclusions:

• Nanotechnology-based siRNA delivery is a promising strategy for cancer treatment.
• Challenges in scale-up, safety, and targeted delivery need to be addressed for clinical translation.
• Recent developments offer hope for revolutionary, personalized cancer therapies.